Chugai Pharmaceutical Co., Ltd. [Head Office: Tokyo, President and CEO: Osamu Okuda] and LTL Pharma Co., Ltd. [Head Office: Tokyo, President and Representative Director: Tetsuo Ito] have announced an agreement under which Chugai will transfer its Japanese business related to the secondary hyperparathyroidism drug “OXAROL® for Injection” to LTL Pharma. Chugai currently holds the manufacturing and marketing authorization for this drug in Japan.
Since 2000, Chugai has been responsible for marketing OXAROL for Injection and providing related information in Japan. Given the product’s lifecycle maturity, Chugai has evaluated its domestic marketing strategy. Following discussions, both companies agreed that Chugai would transfer all assets associated with OXAROL for Injection in Japan, including manufacturing and marketing authorization, to LTL Pharma. LTL Pharma will then assume responsibility for sales and promotion of the drug. LTL Pharma is committed to ensuring the stable and continuous supply of Long-life Medicines and will focus on maintaining and updating the safety and quality data for OXAROL for Injection.
The companies are now working on the necessary administrative and legal procedures to complete the transaction. The transfer of marketing authorization is set for October 1, 2024, with the sales transition expected to be finalized by January 1, 2025. Following these dates, LTL Pharma will take over marketing and information provision activities for OXAROL for Injection in Japan.
Both Chugai and LTL Pharma will collaborate to ensure a stable supply and a smooth transition of the marketing authorization for OXAROL for Injection.
Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs.
